ProteoMediX Raises CHF 5.2 million in financing round

Tuesday, September 4, 2018 @ 8:00 am

ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors.

Find the full media release here.

You may also be interested in

Life Science Cares launches in Switzerland

First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities.
April 19, 2024

ten23 health and Ypsomed collaborate on the commercialization of patch injector

ten23 health and Ypsomed today announced that they are entering into a strategic partnership to advance the commercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses.
April 16, 2024

Orio Therapeutics raises CHF 500,000 for cardioprotective therapy development

Orio Therapeutics secures CHF 500,000 pre-seed funding to fuel the development of cardioprotective therapy for heart attack patients.
April 4, 2024

Newron valuation report "A pivotal year"

March 26, 2024

Stämm scales adherent cells by leveraging 3D printing and microfluidics

March 25, 2024

ten23 health: Partnership with SHL Medical

ten23 health, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, and SHL Medical, a world-leading provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
March 25, 2024